I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3903人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088740, encodeId=1d272088e40f9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=64, createdTime=2019-11-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088789, encodeId=6f072088e8984, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, objectType=article, longId=189616, objectId=bc9018961683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9018961683, replyNumber=0, likeNumber=54, createdTime=2020-10-24, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9018961683, moduleTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc9018961683)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088760, encodeId=1c352088e605e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=67, createdTime=2020-02-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088738, encodeId=98b02088e38be, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=69, createdTime=2019-08-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088771, encodeId=6ecb2088e71c8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=73, createdTime=2020-01-03, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088770, encodeId=d6962088e7019, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, objectType=article, longId=181606, objectId=fdfc181606fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc181606fb, replyNumber=0, likeNumber=61, createdTime=2020-02-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc181606fb, moduleTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc181606fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088746, encodeId=b3fe2088e462d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=64, createdTime=2019-10-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088741, encodeId=93402088e4138, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=57, createdTime=2020-03-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088739, encodeId=d8c72088e39e3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=81, createdTime=2019-07-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088761, encodeId=1e762088e619a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, objectType=article, longId=177982, objectId=e7881e798242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7881e798242, replyNumber=0, likeNumber=69, createdTime=2019-10-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7881e798242, moduleTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7881e798242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088736, encodeId=97422088e3641, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布, objectType=article, longId=162732, objectId=e5cb162e32cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5cb162e32cd, replyNumber=0, likeNumber=64, createdTime=2019-12-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5cb162e32cd, moduleTitle=逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5cb162e32cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088732, encodeId=5e622088e323f, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=52, createdTime=2019-09-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088720, encodeId=ee2d2088e2098, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告, objectType=article, longId=159648, objectId=e51715964873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e51715964873, replyNumber=0, likeNumber=75, createdTime=2019-09-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e51715964873, moduleTitle=Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e51715964873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088745, encodeId=60c42088e45a8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, objectType=article, longId=165942, objectId=8c7e165942ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e165942ca, replyNumber=0, likeNumber=106, createdTime=2020-02-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e165942ca, moduleTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7e165942ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088726, encodeId=b09f2088e264e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=87, createdTime=2019-10-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088717, encodeId=b37c2088e17cc, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验, objectType=article, longId=157056, objectId=382f15e056cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=382f15e056cb, replyNumber=0, likeNumber=63, createdTime=2019-05-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=382f15e056cb, moduleTitle=JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=382f15e056cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088715, encodeId=c53e2088e1508, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=79, createdTime=2019-05-09, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088718, encodeId=26192088e18a8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, objectType=article, longId=158471, objectId=e6371584e194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6371584e194, replyNumber=0, likeNumber=90, createdTime=2019-02-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6371584e194, moduleTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6371584e194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088749, encodeId=27002088e49d6, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, objectType=article, longId=172193, objectId=f8e41e2193df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e41e2193df, replyNumber=0, likeNumber=62, createdTime=2019-06-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e41e2193df, moduleTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e41e2193df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088765, encodeId=89242088e65f7, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内, objectType=article, longId=179417, objectId=35521e94171b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35521e94171b, replyNumber=0, likeNumber=89, createdTime=2020-02-26, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35521e94171b, moduleTitle=JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35521e94171b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-11-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND

2020-10-24

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2020-02-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2019-08-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2020-01-03

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

2020-02-22

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2019-10-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2020-03-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-07-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用

2019-10-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

逆转替卡格雷的抗血小板作用：PB2452的I期临床试验的全部结果现已公布

2019-12-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-09-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告

2019-09-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

2020-02-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-10-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验

2019-05-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2019-05-09

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验

2019-02-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

2019-06-29

柳叶一刀 (审核中...)

前往app查看评论内容

#I期临床试验#

JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内

2020-02-26

科室
- - 订阅+
  - 更多科室
工具
服务